Igenica Lands $14,000,000 Series C Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c0f3c9f5-df4a-4e38-bbaa-eee5a7e20440
Date
1/28/2014
Company Name
Igenica
Mailing Address
863 Mitten Road Burlingame, CA 94010
Company Description
Igenica is a biopharmaceutical company dedicated to the discovery and development of breakthrough antibody-based therapeutics for the treatment of cancer.
Website
http://www.igenica.com
Transaction Type
Venture Equity
Transaction Amount
$14,000,000
Transaction Round
Series C
Proceeds Purposes
As we strengthen our product focus, these funds will be used to advance IGN523 through early clinical trials aimed at safety and clinical activity assessments in acute myelogeneous leukemia. It also will enable us to continue to discover and develop new therapeutics based on our innovative ADC platform to expand Igenica’s pipeline and to increase strategic flexibility as we execute on our business and clinical development plans.
M&A Terms
Venture Investor
The Column Group
Venture Investor
5AM Ventures
Venture Investor
OrbiMed Advisors
Venture Investor
Third Rock Ventures